Ziritaxestat 治疗早期弥漫性皮肤型系统性硬化症:24周IIa期随机双盲安慰剂对照研究
NOVESA 研究为 24 周多中心 IIa 期双盲安慰剂对照试验,纳入早期弥漫性皮肤型系统性硬化症成人患者,随机接受口服 ziritaxestat 600 mg 每日一次(n=21)或安慰剂(n=12)。第 24 周改良 Rodnan 皮肤评分(MRSS)较基线下降 ziritaxestat 组 -8.9 单位 vs 安慰剂组 -6.0 单位(P=0.0411)。ziritaxestat 耐受性良好,最常见治疗相关不良事件为头痛和腹泻。
要点
- 第24周MRSS较基线下降 ziritaxestat 组 -8.9 单位 vs 安慰剂组 -6.0 单位(P=0.0411)。
- ziritaxestat 耐受性良好,最常见治疗相关不良事件为头痛和腹泻。
- 循环 LPA C18:2 显著降低提示靶点结合,血中纤维化生物标志物水平降低。
核心结论
- ziritaxestat 第24周 MRSS 下降显著大于安慰剂;未出现新的安全性信号。
- 生物标志物分析提示 ziritaxestat 可能减少纤维化。
- 调节 autotaxin/LPA 通路可能改善 dcSSc 患者皮肤受累。
研究设计与样本
- NOVESA 为 24 周、多中心、IIa 期、双盲、安慰剂对照研究。
- 成人 dcSSc 患者随机接受口服 ziritaxestat 600 mg 每日一次(n=21)或匹配安慰剂(n=12)。
- 主要疗效终点为第24周 MRSS 较基线变化;次要终点评估安全性和耐受性,其他终点包括皮肤和血液生物标志物。
- NOVESA 患者可进入 104 周开放标签扩展(OLE)。
主要发现
- MRSS 下降 ziritaxestat 组 -8.9 单位 vs 安慰剂组 -6.0 单位(P=0.0411)。
- OLE 中由安慰剂转换为 ziritaxestat 的患者 MRSS 下降与母研究中 ziritaxestat 组观察到的相似。
- ziritaxestat 耐受性良好;最常见治疗相关治疗中出现的不良事件为头痛和腹泻。
- 循环溶血磷脂酸(LPA)C18:2 显著降低,证明 ziritaxestat 靶点结合,血中纤维化生物标志物水平降低。
- 皮肤活检未发现差异表达基因;血液样本中发现109个基因显著变化。
关键数值与推荐
- 主要疗效终点第24周 MRSS 较基线变化:ziritaxestat 组 -8.9 单位 vs 安慰剂组 -6.0 单位(P=0.0411)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We undertook this study to explore the efficacy, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc). METHODS: NOVESA was a 24-week, multicenter, phase IIa, double-blind, placebo-controlled study. Adults with dcSSc were randomized to oral ziritaxestat 600 mg once daily or matching placebo. The primary efficacy end point was change from baseline in modified Rodnan skin score (MRSS) at week 24. Secondary end points assessed safety and tolerability; other end points included assessment of skin and blood biomarkers. Patients in NOVESA could enter a 104-week open-label extension (OLE). RESULTS: Patients were randomized to ziritaxestat (n = 21) or placebo (n = 12). Reduction in MRSS was significantly greater in the ziritaxestat group versus the placebo group (-8.9 versus -6.0 units, respectively; P = 0.0411). Placebo patients switching to ziritaxestat in the OLE showed similar reductions in MRSS to those observed for ziritaxestat patients in the parent study. Ziritaxestat was well tolerated; the most frequent treatment-related treatment-emergent adverse events were headache and diarrhea. Circulating lysophosphatidic acid (LPA) C18:2 was significantly reduced, demonstrating ziritaxestat target engagement, and levels of fibrosis biomarkers were reduced in the blood. No differentially expressed genes were identified in skin biopsies. Significant changes in 109 genes were identified in blood samples. CONCLUSION: Ziritaxestat resulted in significantly greater reduction in MRSS at week 24 than placebo; no new safety signals emerged. Biomarker analysis suggests ziritaxestat may reduce fibrosis. Modulation of the autotaxin/LPA pathway could improve skin involvement in patients with dcSSc. A plain language summary is provided in the Supplementary Material, available on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42477.
引用
- Khanna D, Denton CP, Furst DE, et al. A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023. PMID: 36787101. doi:10.1002/art.42477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。